FDA Brief

Warning letters Devices

FDA warning letter to

Longhorn Vaccines and Diagnostics LLC

High riskIssued Feb 26Posted Mar 24Center for Devices and Radiological Health

Longhorn Vaccines and Diagnostics sold its PrimeStore MTM sample transport device without required quality controls or clearance for claims beyond its approved uses.

What happened

FDA inspected the firm in Bethesda, MD from October 20 to October 30, 2025 and found it had no written procedures for complaints, corrective and preventive action (fixing problems so they don't recur), design control, nonconforming product, rework, supplier control, management review or quality audits until those procedures were written during the inspection itself. FDA also reviewed the firm's website and product brochure and found claims that the device stabilizes and inactivates many organisms and sample types (Ebola, Mpox, Crimean-Congo hemorrhagic fever, stool, blood, urine and others) beyond the uses FDA cleared in DEN170029. Earlier complaints the firm never investigated included leakage, two ingestions in 2022, two skin exposures in 2021, and a 2020 field correction after cyanide gas was released when the device was used with bleach.

What FDA found

  1. The firm did not keep proper complaint files and had no complaint procedure until it wrote one during the inspection, so 13 emailed complaints from 2020 to 2022 were never logged, and complaints were not checked to see if they had to be reported to FDA.

    21 CFR 820.198(a), (a)(1)-(3)
  2. The firm did not review complaints to decide whether an investigation was needed and did not investigate complaints about leaks, cyanide release, ingestion or skin exposure, or record why no investigation was done.

    21 CFR 820.198(b), 820.198(c)
  3. The firm had no procedure for corrective and preventive action until the inspection, and it never analyzed complaints or the 2020 cyanide field correction to find the cause or check that fixes worked.

    21 CFR 820.100(a), (a)(1)-(4)
  4. The firm had no design control procedures until the inspection, and it changed the device (new tube sizes and fill volumes, shelf life raised from 24 to 30 months, tube change) without verification, review or approval.

    21 CFR 820.30(a)-(j)
  5. The firm had no procedure to control or evaluate nonconforming product and no rework procedure until the inspection; underfilled, discolored and leaky lots from contract manufacturers were not evaluated, and reworked lots were not retested.

    21 CFR 820.90(a), 820.90(b)(2)
  6. The firm had no supplier evaluations, no purchasing agreements requiring notification of changes, no management review of the quality system and no quality audits, and it marketed the device for many organisms and sample types outside its cleared uses without FDA clearance.

    21 CFR 820.50, 820.20(c), 820.22; Act sections 501(f)(1)(B) and 502(o), 21 CFR 807.81(a)(3)(ii)

What FDA wants

FDA tells the firm to correct the violations and respond in writing to the Center for Devices and Radiological Health, and notes that any corrective actions must meet the new Quality Management System Regulation that took effect February 2, 2026. The copy of the letter reviewed here does not state a response deadline.

Who should pay attention

  • labs and public health programs that ship infectious samples in transport media
  • contract manufacturers making PrimeStore MTM tubes, media and labels
  • specification developers that design a device but rely on contract manufacturers to make it

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  2. Peter Schiff Enterprises

    FDA warns Peter Schiff Enterprises over unapproved cardiac devices and serious quality system failures.

    High risk
  3. Chirp Innovations, LLC

    FDA warned Chirp Innovations over quality-system gaps, missing adverse-event reporting procedures, and unapproved marketing of its Halo muscle stimulator for menstrual pain.

    High risk
  4. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk